Printed from Voxsanity (voxsanity.com.au) — NCT06499857 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Atrial Fibrillation
Phase 3 Atrial Fibrillation Trial, Recruiting
NCT06499857
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 75 years old
- People with a body mass index (BMI) of 30 or higher (a measure of body weight relative to height)
- People who have a type of irregular heartbeat called atrial fibrillation (AF) — either the kind that comes and goes (paroxysmal) or the kind that lasts longer (persistent) — and who are either expected to have a heart procedure called catheter ablation within the next year, or who are not expected to have that procedure within the next year
- People who are able to give their agreement to participate before any trial activities begin
- People with type 2 diabetes may be included if their blood sugar control measure (HbA1c) is 10% or below, and they are managing their diabetes with basal insulin only, tablet medications, or a combination of both
- People with type 2 diabetes who take certain diabetes medications (SGLT2 inhibitors or TZDs) may be included if they have been on a stable dose of those medications for at least 6 months
- Women who could become pregnant must be using appropriate contraception during the trial
Who may not be able to join:
- People currently taking, or who have taken within the last 90 days, certain diabetes medications known as GLP-1 receptor agonists or DPP4 inhibitors (confirm with trial site for specific medication names)
- People currently taking, or who have taken within the last 90 days, any medication prescribed for weight loss
- People whose body weight has changed by more than 5 kg (11 lb) in the 30 days before screening
- People who have previously had weight-loss (bariatric) surgery
- People with a history of type 1 diabetes
- People currently using mealtime (prandial) insulin
- People who were hospitalised for unstable chest pain (unstable angina) or a mini-stroke (TIA) within the 30 days before screening
- People who have had a blood clot in the lungs (pulmonary embolism) within the 90 days before screening
- People who have had a heart attack, stroke, or similar event within the 90 months before screening (confirm with trial site)
- People with an uncontrolled thyroid condition, based on a specific blood test result at screening
- People with an active cancer diagnosis
- People currently enrolled in another clinical study involving any kind of treatment or intervention
- People who have received any experimental (investigational) drug within the 90 days before this trial
- People who are unable to follow the study procedures
- People who have had sudden pancreas inflammation (acute pancreatitis) within 180 days before screening
- People with a history of long-term (chronic) pancreas inflammation
- People with advanced kidney disease (stage 4 chronic kidney disease, meaning kidney function is significantly reduced)
- People with a personal or family history of a specific type of thyroid cancer (medullary thyroid carcinoma) or a related inherited condition (Multiple Endocrine Neoplasia syndrome type 2)
- People who have previously had a serious allergic reaction to semaglutide or to any ingredient in the medication Wegovy
- People with ongoing inflammatory conditions that require immune-suppressing medications or steroid (glucocorticoid) treatment
- People who have previously participated in this same trial and received at least one dose of the study drug or placebo
- People who are pregnant, breastfeeding, or planning to become pregnant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Silvana Pannain, MD, University of Chicago
Phone: 773-702-3275
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
14 April 2025
Est. completion
1 December 2027
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Time to first AF event detected by routine outpatient monitoring; Change from baseline in AF burden detected by routine outpatient monitoring.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.